BlackRock Fund Advisors boosted its stake in shares of Albany Molecular Research Inc. (NASDAQ:AMRI) by 0.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,128,026 shares of the company’s stock after buying an additional 17,274 shares during the period. BlackRock Fund Advisors owned approximately 6.17% of Albany Molecular Research worth $32,538,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Ngam Advisors L.P. raised its stake in shares of Albany Molecular Research by 2.4% in the first quarter. Ngam Advisors L.P. now owns 165,466 shares of the company’s stock valued at $2,530,000 after buying an additional 3,948 shares during the period. Pacad Investment Ltd. purchased a new stake in shares of Albany Molecular Research during the first quarter valued at $197,000. Moody Aldrich Partners LLC purchased a new stake in shares of Albany Molecular Research during the first quarter valued at $711,000. Capital Impact Advisors LLC raised its stake in shares of Albany Molecular Research by 126.2% in the first quarter. Capital Impact Advisors LLC now owns 49,644 shares of the company’s stock valued at $759,000 after buying an additional 27,700 shares during the period. Finally, Credit Suisse AG raised its stake in shares of Albany Molecular Research by 221.1% in the fourth quarter. Credit Suisse AG now owns 57,569 shares of the company’s stock valued at $1,142,000 after buying an additional 39,642 shares during the period.
Shares of Albany Molecular Research Inc. (NASDAQ:AMRI) traded down 1.10% during midday trading on Thursday, hitting $14.32. The stock had a trading volume of 307,897 shares. The firm’s market capitalization is $494.10 million. Albany Molecular Research Inc. has a one year low of $12.45 and a one year high of $22.48. The firm’s 50-day moving average price is $14.01 and its 200-day moving average price is $14.86.
Separately, Morgan Stanley restated a “buy” rating on shares of Albany Molecular Research in a report on Sunday, May 8th.
In other news, SVP Steven R. Hagen sold 2,361 shares of the stock in a transaction that occurred on Friday, May 13th. The stock was sold at an average price of $12.77, for a total value of $30,149.97. Following the completion of the transaction, the senior vice president now directly owns 37,564 shares of the company’s stock, valued at approximately $479,692.28. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO William S. Marth bought 12,500 shares of the company’s stock in a transaction dated Monday, May 16th. The stock was bought at an average cost of $12.86 per share, with a total value of $160,750.00. Following the completion of the acquisition, the chief executive officer now owns 524,143 shares in the company, valued at approximately $6,740,478.98. The disclosure for this purchase can be found here.
Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).
